Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO’s Price Target
On Monday, REGENXBIO Inc (NASDAQ:RGNX) announced a program update from its ongoing clinical investigation of RGX-314 for wet AMD, a leading cause…
Morgan Stanley Maintains Overweight on Regenxbio, Raises Price Target to $52
Morgan Stanley analyst Vikram Purohit maintains Regenxbio (NASDAQ:RGNX) with a Overweight and raises the price target from $46 to $52.
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application…
Regenxbio’s Earnings Outlook
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement.
Analysts estimate that Regenxbio will report an earnings per share (EPS) of $-1.53.
Expert Ratings for Regenxbio
Analysts have provided the following ratings for Regenxbio (NASDAQ:RGNX) within the last quarter:
Berenberg Initiates Coverage On Regenxbio with Buy Rating, Announces Price Target of $61
Berenberg analyst Caroline Palomeque initiates coverage on Regenxbio (NASDAQ:RGNX) with a Buy rating and announces Price Target of $61.
5 Small-Cap S&P Stocks To Buy With The Most Upside
The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than large-cap stocks.
The Daily Biotech Pulse: Pfizer-BioNTech’s COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio’s AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours:
5 Value Stocks In The Healthcare Sector
What are Value Stocks?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.